Fig. 4

(a) Expression patterns of PRDM16 were responsive to treatment dose. 3 T3-L1 adipocytes were treated with either 0.5% DMSO, 1 μM ROSI or 25–150 μg/ml DBB for 4, 7 or 10 days respectively, followed by PRDM16 primary antibody labelling and FITC-conjugated secondary antibody conjugation. Image acquisition was performed using the IN Cell 2200 Analyzer and all fluorescent images were analysed using the IN Cell Developer software. * denotes statistically significance (ANOVA P < 0.05) as compared to DMSO (vehicle) after 4 days of treatment, ǂ denotes statistically significance (ANOVA P < 0.05) as compared to the vehicle after 7 days of treatment, and # indicates statistically significance (ANOVA P < 0.05) as compared to the vehicle after 10 days of treatment. (b) Western blot analysis was performed to detect the PRDM16 protein levels in 3 T3-L1 and C2C12 cells treated with 0.5% DMSO, 1 μM ROSI or 50–200 μg/ml DBB for 7 days. Beta actin was served as the loading control. (c) Quantification of PRDM16 protein normalised by beta actin and represented by fold expression